Phenylbutazone -loaded nanoparticulate emulgel for the management of rheumatic arthritis: Formulation, optimization, and in vitro evaluation
Journal of Biomaterials Applications · 19.11.2026
DOI: 10.1177/08853282261507873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomaterials Applications, online erschienen am 19.11.2026. Verfasst von Ankita Gupta und 4 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Rheumatoid arthritis is a chronic autoimmune inflammatory disorder requiring long-term therapy that is frequently associated with systemic adverse effects. The present study aimed to develop and characterize a nanoparticulate emulgel containing Phenylbutazone (PBZ) for topical delivery to manage pain and swelling associated with rheumatoid arthritis. PBZ-loaded chitosan nanoparticles were prepared by the ionic gelation method followed by ultrasonication. Drug-excipient compatibility was evaluated by Fourier Transform Infrared (FTIR) spectroscopy, and nanoparticles were optimized by Box-Behnken design comprising 15 experimental runs. The nanoparticles were characterized for particle size, encapsulation efficiency, and in vitro drug release, while the emulgel was characterized for pH, viscosity, drug content, surface morphology by scanning electron microscopy (SEM), and an in vitro protein denaturation inhibitory activity. The prepared nanoparticles showed a particle size range of 229–502 nm with an encapsulation efficiency exceeding 61-91%. In vitro drug release studies demonstrated cumulative drug release of 76.68 ± 2.05% and 90.52 ± 2.32% at pH 7.4 and 5.5, respectively, over 72 hours. The optimized emulgel formulation exhibited a pH of 6.7 ± 0.30, viscosity of 20,000 ± 700 mPa · s, and a drug content of 90.23 ± 7.47%. SEM analysis confirmed spherical nanoparticles with an average particle size of approximately 211 nm. In vitro protein denaturation inhibition assay revealed that the prepared emulgel inhibited protein denaturation by 71.88 ± 4.74%, compared with 75.63 ± 5.41% for the standard drug, demonstrating a significant difference (
Zitieren
APA
Gupta, A., Kenwat, R., Singh, V. K., Bhuwane, N., & Singh, V. D. (2026). Phenylbutazone -loaded nanoparticulate emulgel for the management of rheumatic arthritis: Formulation, optimization, and in vitro evaluation. Journal of Biomaterials Applications. https://doi.org/10.1177/08853282261507873
Vancouver
Gupta A, Kenwat R, Singh VK, Bhuwane N, Singh VD. Phenylbutazone -loaded nanoparticulate emulgel for the management of rheumatic arthritis: Formulation, optimization, and in vitro evaluation. Journal of Biomaterials Applications. 2026. doi:10.1177/08853282261507873
BibTeX
@article{Gupta2026,
author = {Gupta, Ankita and Kenwat, Rameshroo and Singh, Vijay Kumar and Bhuwane, Nagendra and Singh, Veena Devi},
title = {Phenylbutazone -loaded nanoparticulate emulgel for the management of rheumatic arthritis: Formulation, optimization, and in vitro evaluation},
journal = {Journal of Biomaterials Applications},
year = {2026},
doi = {10.1177/08853282261507873}
}
EUVIMED